Periorbital edema associated with alpelisib

Elizabeth A. Dao, LSU Health Sciences Center - New Orleans
Saira J. George, The University of Texas MD Anderson Cancer Center, Houston, TX
Meghan M. Heberton, The University of Texas MD Anderson Cancer Center, Houston, TX
Omar Pacha, The University of Texas MD Anderson Cancer Center, Houston, TX
Craig A. Kovitz, The University of Texas MD Anderson Cancer Center, Houston, TX
Anisha B. Patel, The University of Texas MD Anderson Cancer Center, Houston, TX
Rhea M. Phillips, The University of Texas MD Anderson Cancer Center, Houston, TX

Erratum to article includes Declaration of Patient Consent statement that was not included in the published version of the article. It verifies that patient consent was obtained by the authors. See https://doi.org/10.1016/j.ctarc.2022.100654

Abstract

Alpelisib is an alpha isoform-specific phosphatidylinositol 3-kinase (PI3K) inhibitor approved for use in the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor (HER2)-negative metastatic breast cancer in combination with fulvestrant. Hyperglycemia, rash, and gastrointestinal upset are the most commonly reported adverse events associated with alpelisib. Although rash is a known on-target effect of alpelisib, patients typically present with a morbilliform rash. We describe two cases of periorbital edema associated with alpelisib. We discuss the clinical findings, management, and prognosis of this unique reaction. These cases highlight the importance of early involvement of dermatology to manage adverse cutaneous events associated with alpelisib.